Studies

Interventional Not yet recruiting Phase 1 Enrollment (Estimated) Enrollment 10 (Estimated)

View on ClinicalTrials.gov NCT07707986 Other Study ID: WKMU-EV-MELSAFE-001

Safety of Topical Exosome-Containing Liquid in Healthy Volunteers for Future Surgical Wound Use

See official title

Sponsor: See the organization West Kazakhstan Marat Ospanov State Medical University

First Submitted: July 7, 2026

Last Update Posted: July 16, 2026

Brief Summary

This Phase 1 split-site pilot study will evaluate the safety and dermal tolerability of a topical exosome-containing liquid in 10 healthy adult volunteers. The investigational liquid will be applied to a small defined area of intact skin. A vehicle liquid without exosomes may be applied to a matched contralateral skin site as a control. The study will assess local skin reactions, systemic adverse events, vital signs, clinical laboratory parameters, and feasibility of topical administration. No melanoma lesion, surgical wound, burn wound, or artificial skin wound will be induced in participants in this Phase 1 safety study.

Conditions

  • Healthy Volunteers (HV)
  • •
  • Skin Irritation

Intervention / Treatment

  • Biological Exosome-Containing Liquid
  • Other Vehicle Liquid

Contacts and Locations

Aktobe, Aktobe

Kazakhstan, 030012

ATMP center of West Kazakhstan Marat Ospanov Medical University

Participation Criteria

Participant Groups/Arms

Exosome-Containing Liquid and Vehicle-Control Skin Sites

EXPERIMENTAL

Healthy adult volunteers will receive topical exosome-containing liquid applied to a small defined area of intact skin. In the split-site design, vehicle liquid without exosomes will be applied to a matched contralateral intact skin site as a control. No melanoma lesion, surgical wound, burn wound, or artificial skin wound will be induced.

Keywords

  • exosomes
  • •
  • extracellular vesicles
  • •
  • topical exosome-containing liquid
  • •
  • healthy volunteers
  • •
  • skin tolerability
  • •
  • skin irritation
  • •
  • phase 1
  • •
  • first-in-human
  • •
  • post-melanoma-excision wound
  • •
  • surgical wound repair
  • •
  • postoperative wound healing
  • •
  • Dermal Tolerability
  • •
  • dermal safety

References

Hu JC, Zheng CX, Sui BD, Liu WJ, Jin Y. Mesenchymal stem cell-derived exosomes: A novel and potential remedy for cutaneous wound healing and regeneration. World J Stem Cells. 2022 May 26;14(5):318-329. doi: 10.4252/wjsc.v14.i5.318.

Welsh JA, Goberdhan DCI, O'Driscoll L, Buzas EI, Blenkiron C, Bussolati B, Cai H, Di Vizio D, Driedonks TAP, Erdbrugger U, Falcon-Perez JM, Fu QL, Hill AF, Lenassi M, Lim SK, Mahoney MG, Mohanty S, Moller A, Nieuwland R, Ochiya T, Sahoo S, Torrecilhas AC, Zheng L, Zijlstra A, Abuelreich S, Bagabas R, Bergese P, Bridges EM, Brucale M, Burger D, Carney RP, Cocucci E, Crescitelli R, Hanser E, Harris AL, Haughey NJ, Hendrix A, Ivanov AR, Jovanovic-Talisman T, Kruh-Garcia NA, Ku'ulei-Lyn Faustino V, Kyburz D, Lasser C, Lennon KM, Lotvall J, Maddox AL, Martens-Uzunova ES, Mizenko RR, Newman LA, Ridolfi A, Rohde E, Rojalin T, Rowland A, Saftics A, Sandau US, Saugstad JA, Shekari F, Swift S, Ter-Ovanesyan D, Tosar JP, Useckaite Z, Valle F, Varga Z, van der Pol E, van Herwijnen MJC, Wauben MHM, Wehman AM, Williams S, Zendrini A, Zimmerman AJ; MISEV Consortium; Thery C, Witwer KW. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. J Extracell Vesicles. 2024 Feb;13(2):e12404. doi: 10.1002/jev2.12404.

Outcome Measures